Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration

Completed

• Conditions: End-stage Renal Disease
• Interventions: Other: Hemodiafiltration

• Registration Number: NCT02576873
• Lead Sponsor: Chulalongkorn University

Brief Summary

A retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in King Chulalongkorn Memorial Hospital between 2001-2013 to determine the survival rate as well as other long-term outcome.

Detailed Description

Growing evidences suggested the superiority of high-efficiency hemodiafiltration (HDF) which could provide both diffusion and convection in a single therapy compared with the conventional hemodialysis. However, the long-term, upto 10 years, outcome still limited. This retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in a single-center, King Chulalongkorn Memorial Hospital, between 2001-2013 to determine the survival rate as well as other long-term outcome

Study Timeline

• Study Start: 2014-03
• Primary Completion: 2015-10
• Study First Submitted: 2015-10-13
• Study First Submitted QC: 2015-10-13
• Study First Posted: 2015-10-15
• Study Completion: 2016-03
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-26
• Last Update Posted: 2016-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Aged 18 years or more
• Be diagnosed end-stage renal disease for more than one year
• Have been regularly received long-term hemodiafiltration for more than 6 months.

Exclusion Criteria

• Patients who received hemodiafiltration less than 6 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hemodiafiltration	Hemodiafiltration	End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months

Primary Outcome Measures

Name	Time	Method
Survival rate	10 years	The Kaplan-Meier survival curve and mean survival time will be demonstrated for primary outcome.

Secondary Outcome Measures

Name	Time	Method
Comparison of survival differences between patients who start renal replacement therapy with HDF and who switched from hemodialysis as well as between diabetic and non-diabetic patient.	10 years	Survival differences between groups will be evaluated with the Kaplan-Meier method and compared using the log-rank test. The comparative groups include: * Patient who start renal replacement therapy with HDF (incident cases) vs. who switched from hemodialysis (prevalence cases); * Diabetic vs. Non-diabetic patients
Factors that associated with all-cause mortality	10 years	univariate and multivariate analysis the factors that might affected the long-term outcomes. The factors include dialytic parameters (spKt/Vurea, TAC urea), nutritional parameters (nPNA, albumin), inflammatory parameter (hsCRP), and biochemical parameters (BUN, Cr, Ca, Phosphate, iPTH, beta2-microglobulin, Hb, Ferritin, Transferrin saturation, Cholesterol, Triglyceride, HDL, and LDL)

Trial Locations

Locations (1)

King Chulalongkorn Memorial Hospital; 🇹🇭 Pathumwan, Bangkok, Thailand